Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595
Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.
The two parallel trials described within this study provide the first phase 3 data for the dual inhibition of IL-17A and IL-17F with bimekizumab within the full spectrum of axSpA. This study aimed to present the first phase 3 efficacy and safety data for bimekizumab across the full axSpA spectrum from two parallel trials in patients with nr-axSpA (BE MOBILE 1) and r-axSpA (BE MOBILE 2).
These data clearly demonstrate that treatment with bimekizumab resulted in rapid, clinically relevant improvements in disease manifestations, compared with placebo, and was well tolerated.